26 May 2013
Keywords: lilly, initiates, ph, iii, gbm, enzastaurin, trial
Article | 20 March 2006
US drug major Eli Lilly has initiated a Phase III study of enzastaurin, its investigational, targeted oral agent, in the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
20 March 2006
24 May 2013
© 2013 thepharmaletter.com